Good news
Today, Salubris announced that two new drugs - Xinliting (Fultagliptin benzoate tablet) and FoLitan®(Allisartan and Amlodipine tablets) are newly listed in the ‘National Basic Medical Insurance, work-related injury insurance and maternity insurance drug Catalogue (2024)’ Category B scope through negotiations.
Xinliting (Fultagliptin benzoate tablet)
Xinliting as a class 1 innovative drug in China, is a dipeptidyl peptidase 4 (DPP-4) inhibitor used to improve blood sugar control in adults with type 2 diabetes (both monotherapy and combination therapy when metformin hydrochloride alone is not effective in controlling blood sugar).
Studies have shown that Xinliting can inhibit the activity of DPP-4, reduce the degradation of DPP-4 to glucagon-like peptide-1 (GLP-1), increase the concentration of GLP-1 in the body, thereby increase insulin release, and reduce glucagon level in a glucose-dependent manner and blood sugar. It has the characteristics of rapid oral absorption, long lasting effect, high selectivity and good safety, etc., which can meet the long-term drug needs of patients.[1]
FoLitan®(Allisartan and Amlodipine tablets)
The new drug, FoLitan®, is a domestic original ARB/CCB compound preparation for the treatment of essential hypertension.
The composition of FoLitan®is classic and highly reliable, and its antihypertensive efficacy has been fully validated in clinical studies.[2]
FoLitan®covers more subdivided areas of hypertension patients, which forms strategic synergy with Salubris’ already listed class 1 innovative drug Xinlitan (Allisartan ester tablets), enriching the innovative product pipeline in the field of hypertension and enhancing Salubris’ comprehensive competitiveness in the field of chronic cardiovascular disease.
References:
1. Label of Fultagliptin benzoate tablet
2. Label of Allisartan and Amlodipine tablets
In the future, Salubris will continue to adhere to the concept of "patient-centered", deepen the field of chronic diseases, focus on innovative drug research and development, continuously improve the accessibility of drugs, meet unmet clinical needs, and improve the health and well-being of patients with scientific and technological innovation.
Statement:
1. The purpose of this material is to provide relevant knowledge in the field of disease, improve the level of disease awareness, and non-advertising use.
2. The information in this document is for reference only. Please follow the advice or guidance of your doctor or other health care professional.
